Legend Biotech Corporation appointed Ingrid Zhang as Chief Executive Officer and principal executive officer, effective September 15, 2026. Ms. Zhang succeeds Alan Bash, who served as interim CEO since July 2026 and will resume his role as President of CARVYKTI. Ms. Zhang previously held senior commercial leadership roles at Novartis International, including Chief Commercial Officer and President of China businesses, as well as positions at AstraZeneca, Pfizer, and McKinsey & Company. Her employment agreement includes a $950,000 annual base salary, a target cash bonus of 90% of base salary, an initial restricted stock unit award valued at least $10 million, and a $150,000 signing bonus subject to clawback provisions. Legend Biotech is a global biopharmaceutical company specializing in cell therapy treatments for cancer.

Legend Biotech reported second quarter 2026 financial results showing total revenue of $387.5 million, a significant increase from $255.1 million in the prior year period. Collaboration revenue rose to $326.1 million driven by CARVYKTI sales under the Janssen agreement, while license and other revenue reached $61.4 million due to a $56.0 million milestone payment from Janssen. The company achieved net income of $33.2 million compared to a net loss of $125.4 million in Q2 2025. Operating income turned positive at $57.7 million, reversing an operating loss of $21.9 million in the prior year. Legend Biotech also announced the appointment of Alan Bash as Interim Chief Executive Officer and completed a public offering of 7,700,000 American Depositary Shares for net proceeds of approximately $212 million. The company operates in the biotechnology industry, specializing in the discovery, development, manufacturing, and commercialization of cell therapies for oncology.

Legend Biotech Corporation appointed Alan Bash as Interim Chief Executive Officer effective July 24, 2026. The Compensation Committee approved a bi-weekly cash compensation of $12,019 for Mr. Bash, payable with each paycheck starting July 27, 2026, in addition to his existing role as President of the CARVYKTI Business Unit. Furthermore, the company granted him restricted stock units valued at $50,000 on August 14, 2026, vesting over three years with one-third vesting annually on the anniversaries of July 27, 2026. Legend Biotech Corporation operates in the biotechnology industry, focusing on the development and commercialization of CAR T-cell therapies for cancer treatment.

Ying Huang resigned as Chief Executive Officer and Board member effective July 24, 2026. The Board appointed Alan Bash, formerly President of CARVYKTI, as Interim Chief Executive Officer and interim principal executive officer. Legend Biotech Corporation is a biotechnology company focused on developing and commercializing CAR-T cell therapies.